Mirdametinib

N/A

Report date: 2026/05/24 20:00:34
NME

Base Information

Drug NameMirdametinib
Drug Alias NameGOMEKLIEzmeklyPD-325901PD-0325901
ClassificationSmall molecules
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsSolid tumoursPIK3CA-Related Overgrowth SpectrumLymphatic Abnormalities +[19] 
Global Approved IndicationsNeurofibromatosis 1Neurofibroma, Plexiform
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/02/11
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteCalifornia Pacific Medical CenterMerck Europe Bv +[9] 
Inactive CompaniesArray BiopharmaPfizer IncUniversity Of Alabama At Birmingham
Active IndicationsSolid tumoursPIK3CA-Related Overgrowth SpectrumLymphatic Abnormalities +[15] 
Inactive IndicationsColonic NeoplasmsColorectal NeoplasmsBreast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG